MCRO Stock Overview

Macro Group Pharmaceuticals (Macro Capital) S.A.E. More details

MCRO fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	2/6

Risk Analysis

Interest payments are not well covered by earnings

Earnings have declined by 71% per year over past 5 years

Does not have a meaningful market cap (EGP1B)

Dividend of 5.13% is not well covered by free cash flows

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Macro Group Pharmaceuticals (Macro Capital) S.A.E Competitors

McPherson's

ASX:MCP

AU$35.3m

TS Trillion

KOSDAQ:A317240

₩25.8b

Natural Alternatives International

NasdaqGM:NAII

US$21.4m

Outin Futures

KOSDAQ:A227610

₩32.0b

Price History & Performance

Summary of share price highs, lows and changes for Macro Group Pharmaceuticals (Macro Capital)E
Historical stock prices
Current Share Price	ج.م2.08
52 Week High	ج.م3.00
52 Week Low	ج.م1.58
Beta	0.016
1 Month Change	1.96%
3 Month Change	-18.43%
1 Year Change	-28.77%
3 Year Change	-40.23%
5 Year Change	n/a
Change since IPO	-53.88%

Recent updates

Shareholder Returns

	MCRO	EG Personal Products	EG Market
7D	1.0%	-1.0%	0.2%
1Y	-28.8%	-10.1%	15.5%

Return vs Industry: MCRO underperformed the EG Personal Products industry which returned -9.3% over the past year.

Return vs Market: MCRO underperformed the EG Market which returned 15.5% over the past year.

Price Volatility

Is MCRO's price volatile compared to industry and market?
MCRO volatility
MCRO Average Weekly Movement	4.1%
Personal Products Industry Average Movement	5.3%
Market Average Movement	4.8%
10% most volatile stocks in EG Market	8.4%
10% least volatile stocks in EG Market	2.9%

Stable Share Price: MCRO has not had significant price volatility in the past 3 months compared to the EG market.

Volatility Over Time: MCRO's weekly volatility (4%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2002	n/a	Hisham Wasfy	www.macro-egy.com

Macro Group Pharmaceuticals (Macro Capital) S.A.E. operates as a cosmeceuticals manufacturing company in Egypt and internationally. It is involved in the production of pharmaceutical and cosmetic products, such as skin care, hair care, oral care, female intimate care, anti-scar, antiseptics, and topical muscle relaxants, as well as flavors, colors, and scents. The company also manufactures solid and liquid soap, herbal medicines, products and extracts, nutritional supplements, baby food, and special food products and distribution.

Macro Group Pharmaceuticals (Macro Capital) S.A.E Fundamentals Summary

How do Macro Group Pharmaceuticals (Macro Capital)E's earnings and revenue compare to its market cap?
MCRO fundamental statistics
Market cap	ج.م1.17b
Earnings (TTM)	-ج.م38.10m
Revenue (TTM)	ج.م519.97m

2.2x

P/S Ratio

-30.7x

P/E Ratio

Is MCRO overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MCRO income statement (TTM)
Revenue	ج.م519.97m
Cost of Revenue	ج.م196.85m
Gross Profit	ج.م323.12m
Other Expenses	ج.م361.22m
Earnings	-ج.م38.10m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.068
Gross Margin	62.14%
Net Profit Margin	-7.33%
Debt/Equity Ratio	362.3%

How did MCRO perform over the long term?

See historical performance and comparison

Dividends

5.1%

Current Dividend Yield

42%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/03/22 19:17
End of Day Share Price	2025/03/20 00:00
Earnings	2024/12/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Macro Group Pharmaceuticals (Macro Capital) S.A.E is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ahmed Moataz	EFG-Hermes Research